Catalent is expanding and adding 36 jobs at its Indiana biologics plant

Catalent is expanding and adding jobs to the biologics plant it acquired last year in Bloomington, Indiana. (Cook Pharmica)

Somerset, New Jersey-based CDMO Catalent says it has racked up 20 drug approvals for the Indiana biologics plant it picked up in its $950 million deal for Cook Pharmica last year. With that, Catalent says it needs to expand the facility and add workers.

Catalent Pharma Solutions will invest nearly $14 million to expand biologics packaging capabilities and capacity at the Bloomington, Indiana, biologics manufacturing facility. It expects to add 36 jobs as a result.

It is building a 15,000-square-foot facility infrastructure that it says will include five packaging suites and a quality control laboratory. The company expects to have all of that complete in February of next year but will phase the installation and commissioning of new equipment throughout the year.

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

Catalent acquired the 875,000-square-foot biologics development and manufacturing facility in 2017 when it agreed to pay $750 million to privately held Cook Group on closing and the rest in $50 million installments over the next four years. The Cook CDMO business had revenues of $179 million in 2016, the year before Catalent acquired it.

RELATED: Catalent extends expansion with $133M deal for Juniper Pharmaceuticals

When it got the Indiana plant, CFO Matt Walsh said the facility was running only about 40% capacity, leaving lots of room for organic growth. He said about half of the plant’s footprint was available for expansion, which the company saw as a benefit of the deal, allowing it to grow “without substantial investment in the near term.”

But the acquisition has had its challenges. In May the FDA  issued the plant a Form 483, after inspectors found “an unacceptably high number of mold recoveries in the classified rooms used for the manufacture” of bulk drugs. The agency said the number of mold recoveries has been “trending” higher since 2015. Catalent said it had "self-identified" most of the items in the observations and a corrective and preventive action plan (CAPA) was in place before the preapproval inspection.

Catalent followed the Cook deal up this year with a much smaller deal, paying $133 million to buy Juniper Pharmaceuticals. A key target of that deal was Juniper’s Nottingham, U.K.-based pharma services division, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing.

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.